Literature DB >> 3805777

Murine model of intracerebral toxoplasmosis.

J M Hofflin, F K Conley, J S Remington.   

Abstract

We established a murine model of toxoplasmic encephalitis by using intracerebral inoculation with Toxoplasma gondii tachyzoites. Normal mice survived, but immunosuppressed mice died from progressive disease. In normal mice, necrosis developed at the site of inoculation, surrounded by areas with intense mononuclear inflammation and cyst formation; tachyzoites were not detectable after two weeks. Immunosuppressed mice had even-larger areas of tissue destruction, and tachyzoites were always detectable. Brains from cortisone-treated mice had numerous tachyzoites, but scant inflammation. Brains from cyclophosphamide-treated mice revealed cysts and a variable degree of inflammation. Compared with brains from controls, brains from cyclosporine-treated mice revealed attenuated inflammation; however, there were fewer tachyzoites and less tissue destruction than in the brains from cortisone-treated mice. The spectrum of histological findings observed in the model is similar to that observed in brains from humans with toxoplasmic encephalitis.

Entities:  

Mesh:

Year:  1987        PMID: 3805777     DOI: 10.1093/infdis/155.3.550

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

Review 1.  Toxoplasma gondii and ocular toxoplasmosis: pathogenesis.

Authors:  C E Pavesio; S Lightman
Journal:  Br J Ophthalmol       Date:  1996-12       Impact factor: 4.638

2.  Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis?

Authors:  Sibylle Winterhalter; Katja Severing; Johannes Stammen; Anna Karina Maier; Erhard Godehardt; Antonia Maria Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-05-02       Impact factor: 3.117

3.  In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice.

Authors:  C Piketty; F Derouin; B Rouveix; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Measurement of the active toxoplasma retinochoroiditis lesion size during the disease course with swept-source optical coherence tomography angiography: A retrospective image analysis.

Authors:  Ferdane Atas; Mahmut Kaya; Tugce Toprak; Betul Akbulut Yagci; Alper Selver; Ali Osman Saatci
Journal:  Int Ophthalmol       Date:  2021-07-23       Impact factor: 2.031

5.  A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice.

Authors:  Y Suzuki; K Joh; M A Orellana; F K Conley; J S Remington
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

6.  High risk of developing toxoplasmic encephalitis in AIDS patients seropositive to Toxoplasma gondii.

Authors:  R Zangerle; F Allerberger; P Pohl; P Fritsch; M P Dierich
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

7.  Risk factors for severe disease due to Toxoplasma gondii in HIV-positive patients.

Authors:  H J Stellbrink; R Führer-Burow; A Raedler; H Albrecht; S Fenske
Journal:  Eur J Epidemiol       Date:  1993-11       Impact factor: 8.082

8.  Temporal and spatial distribution of Toxoplasma gondii differentiation into Bradyzoites and tissue cyst formation in vivo.

Authors:  Manlio Di Cristina; Daniela Marocco; Roberto Galizi; Carla Proietti; Roberta Spaccapelo; Andrea Crisanti
Journal:  Infect Immun       Date:  2008-05-27       Impact factor: 3.441

Review 9.  Role of gamma interferon in Toxoplasma gondii infection.

Authors:  C S Subauste; J S Remington
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

Review 10.  Current recommendations and future prospects in the treatment of toxoplasmosis.

Authors:  R E McCabe; S Oster
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.